FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

FDA approved a supplemental ANDA from Zydus Lifesciences Limited for ambrisentan, authorizing a generic version for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)